糖尿病患Thiazolidinediones使用與罹患大腸直腸癌的風險

Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients with Diabetes: A nationwide, population-based, case-control study

陳世偉(Shih-Wei Chen)

指導教授 ： 陳保中

國立臺灣大學/公共衛生學院/職業醫學與工業衛生研究所/碩士(2012年)

https://doi.org/10.6342/NTU.2012.10495

摘要

研究目的：
根據目前許多臨床前的動物實驗或細胞實驗的結果顯示，PPAR-γ agonists具有抑制大腸直腸癌的作用。本研究以合成的PPAR-γ agonists（Thiazolidinediones, TZDs)來評估PPAR-γ agonists的使用與大腸直腸癌發生的關係。

研究方法：
研究設計為利用台灣全民健保資料庫進行全國性人口為基礎的病例對照研究，病例個案選取為診斷糖尿病至少365天於2000至2008年被診斷為大腸直腸癌之新發生個案，並以性別、年齡和糖尿病的診斷年齡為配對條件，隨機選取對照組。於24,496符合資格的病例和對照個案中，以條件邏輯回歸分析法評估TZDs藥物的使用與大腸直腸癌風險的關係。並另外進行附加研究，評估TZDs藥物同時與低劑量aspirin或非類固醇類止痛藥(NSAIDs)併用對大腸直腸癌風險的關係。

研究結果：
與沒有使用TZDs藥物的人比較之下，有使用TZDs藥物的人其罹患大腸直腸癌的風險降低，odds ratio為 0.86 (95% CI, 0.79-0.94)。此外，TZDs藥物與低劑量aspirin或NSAIDs併用下，大腸直腸癌的風險仍然下降。

結論：
TZDs的使用會降低糖尿病人發生大腸直腸癌的風險，此結果值得進一步的研究來確認。

關鍵字

胰島素增敏劑 ； 糖尿病 ； 大腸直腸癌

並列摘要

Objective
Pre-clinical data suggest that peroxisome proliferator-activated receptor gamma (PPARγ) agonists have antineoplastic effects in colorectal cancer. We aimed to assess the association between the use of synthetic PPARγ agonists, represented by thiazolidinediones (TZDs), and the risk of developing colorectal cancer.

Research Design and Methods
We conducted a nationwide, population-based, case-control study using the Taiwan National Health Insurance Research Database. Cases were defined as patients who were diagnosed with diabetes at least 365 days prior to a new diagnosis of colorectal cancer between 2000 and 2008. We randomly selected diabetic controls for each case, which were matched by gender, age, and the duration of diabetes. Among the 24,496 eligible cases and controls, we used conditional logistic regression to assess the risk of colorectal cancer in association with use of TZDs. An additional analysis was conducted to assess the effects of concomitant use of TZDs and low-dose aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of colorectal cancer.

Results
A decreased risk of colorectal cancer was observed in patients who had used TZDs compared with those who had never used TZDs (adjusted odds ratio, 0.86; 95% CI, 0.79-0.94). Furthermore, the benefit of a decreased colorectal cancer risk was also found with concomitant use of TZDs and low-dose aspirin or NSAIDs.

Conclusions
The use of TZDs may be associated with a decreased risk of colorectal cancer in patients with diabetes. Further studies are warranted to confirm our findings.

並列關鍵字

Thiazolidinediones ； Diabetes ； Colorectal Cancer

參考文獻

1. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995; 83: 835-839.

2. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000; 405: 421-424.

3. Forman BM, Tontonoz P, Chen J, et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995; 83: 803-812.

4. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 1998; 4: 1046-1052.

5. Mansen A, Guardiola-Diaz H, Rafter J, et al. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun. 1996; 222: 844-851.